Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 4.0% from a year ago
Total equity stood at $234.64M at the end of Q1 FY2026, up 4.0% from a year earlier and up 0.9% from the prior quarter.
Context
- Total equity amounted to 96.9% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +4.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 232.64M USD
- Year-over-year change
- +95345458.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 232.64M | +95345458.6% |
| FY2024 | 2024-12-31 | (244) | — |
Total Equity vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's Mar 2026 total equity of $234.64M is the 8th highest of the 10 companies compared; the peer median is $247.11M.
- Its year-over-year change of +4.0% is the 8th highest of 10, against a peer median of +2648.6%.
- Total equity amounts to 96.9% of total assets for DMAA, versus a peer median of 96.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
TACOUBerto Acquisition Corp. Unit | Mar 2026 | $299.17M | +51573.2% | — | 96.0% |
| Mar 2026 | $299.17M | +51573.2% | — | 96.0% | |
TACHTitan Acquisition Corp. | Mar 2026 | $274.46M | +89537175.4% | — | 95.1% |
OYSEOyster Enterprises II Acquisition Corp | Mar 2026 | $253.4M | +533077.1% | — | 96.6% |
| Mar 2026 | $247.11M | +8.6% | — | 99.7% | |
| Mar 2026 | $242.22M | +6.6% | — | 99.4% | |
| Mar 2026 | $240M | +2648.6% | — | 95.8% | |
| Mar 2026 | $234.64M | +4.0% | — | 96.9% | |
| Mar 2026 | $210.16M | -4.7% | — | 86.7% | |
| Mar 2026 | -$13.79M | -104.8% | — | 4.4% | |
| Peer median (excluding DMAA) | $247.11M | +2648.6% | — | 96.0% | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 1.35K | 6.14K |
| Short-term Investments | 0 | 0 |
| Net Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 0 | 6.05K |
| Total Current Assets | 4.99K | 12.19K |
| Property, Plant & Equipment (Net) | 0 | 0 |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 0 | 0 |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 546 | 239.91M |
| Total Non-current Assets | 546 | 239.91M |
| Total Assets | 551 | 239.92M |
| Account Payables | 0 | 222.18K |
| Short-term Debt | 662 | 0 |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 0 | 0 |
| Other Current Liabilities | 56 | 0 |
| Total Current Liabilities | 796 | 376.17K |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 0 | 6.9M |
| Total Non-current Liabilities | 0 | 6.9M |
| Total Liabilities | 796 | 7.28M |
| Common Stock | 986 | 239.91M |
| Retained Earnings | (279) | (7.27M) |
| Accumulated OCI | 0 | 0 |
| Other Stockholders Equity | (985) | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | (244) | 232.64M |
| Total Debt | 662 | 0 |
| Net Debt | 661 | (6.14K) |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.